Why Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity Trials - And What's Next

Simply Wall St.03-14

In recent weeks, Viking Therapeutics has pushed its obesity candidate VK2735 further into late-stage development, completing or nearly completing enrollment for its Phase 3 VANQUISH trials and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619127301?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-14 02:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619127301","market":"sg","top_or_hot":-1,"title":"Why Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity Trials - And What's Next","media":"Simply Wall St.","content":"<div>\n<p>In recent weeks, Viking Therapeutics has pushed its obesity candidate VK2735 further into late-stage development, completing or nearly completing enrollment for its Phase 3 VANQUISH trials and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/why-viking-therapeutics-vktx-is-up-126-after-fast-tracking-v\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity Trials - And What's Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity Trials - And What's Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-14 02:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/why-viking-therapeutics-vktx-is-up-126-after-fast-tracking-v><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent weeks, Viking Therapeutics has pushed its obesity candidate VK2735 further into late-stage development, completing or nearly completing enrollment for its Phase 3 VANQUISH trials and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/why-viking-therapeutics-vktx-is-up-126-after-fast-tracking-v\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/why-viking-therapeutics-vktx-is-up-126-after-fast-tracking-v","article_id":"2619127301","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/why-viking-therapeutics-vktx-is-up-126-after-fast-tracking-v","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619127301","pubTimestamp":1773426910,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent weeks, Viking Therapeutics has pushed its obesity candidate VK2735 further into late-stage development, completing or nearly completing enrollment for its Phase 3 VANQUISH trials and preparing an oral Phase 3 program after positive Phase 2 data and FDA feedback.\nThis acceleration across both injectable and oral formulations of VK2735 strengthens the company’s position in the growing market for flexible obesity treatments and heightens the importance of upcoming clinical readouts...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4599":"减肥药","SSI":"Stage Stores Inc","VKTX":"Viking Therapeutics, Inc.","BK4588":"碎股"},"translate_title":"为什么Viking Therapeutics(VKTX)在快速跟踪VK2735进入后期肥胖试验后股价上涨12.6%-以及下一步是什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSI":1.5,"VKTX":1.5},"content_text":"In recent weeks, Viking Therapeutics has pushed its obesity candidate VK2735 further into late-stage development, completing or nearly completing enrollment for its Phase 3 VANQUISH trials and preparing an oral Phase 3 program after positive Phase 2 data and FDA feedback. This acceleration across both injectable and oral formulations of VK2735 strengthens the company’s position in the growing market for flexible obesity treatments and heightens the importance of upcoming clinical readouts for its long-term business profile. Next, we’ll examine how advancing VK2735 into late-stage trials shapes Viking Therapeutics’ investment narrative and risk-reward profile. This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.AdvertisementViking Therapeutics Investment Narrative RecapTo own Viking Therapeutics today, you have to believe VK2735 can successfully clear late stage trials and eventually translate into a commercial obesity franchise, despite ongoing losses and no revenue. The latest update on VANQUISH enrollment and the planned Phase 3 oral program reinforces the central near term catalyst of pivotal VK2735 data, while leaving the biggest risk intact: any clinical delay or safety issue could still materially disrupt the story. The most relevant recent development is Viking’s move to advance oral VK2735 into Phase 3 after positive Phase 2 data and FDA feedback. This complements the VANQUISH injectable trials and keeps both formulations aligned with the same critical catalyst path, where each upcoming readout will add or subtract confidence from the overall obesity thesis. Yet even with this progress, investors still need to weigh the risk that Viking’s rising R&D spend and reliance on its US$706,000,000 cash balance could... Read the full narrative on Viking Therapeutics (it's free!)Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This requires revenue growth from no revenue today and a $372.5 million earnings increase from -$359.6 million today.Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 161% upside to its current price.Exploring Other PerspectivesVKTX 1-Year Stock Price Chart Twenty two members of the Simply Wall St Community value Viking between US$27.89 and US$278.88 per share, highlighting very different expectations. As you compare those views, remember that everything hinges on VK2735’s late stage trial outcomes and the company’s ability to fund this program without eroding long term shareholder value.Explore 22 other fair value estimates on Viking Therapeutics - why the stock might be worth over 7x more than the current price!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Viking Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.Looking For Alternative Opportunities?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Uncover the next big thing with 32 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619127301","isCrawlerRequest":true}